妊娠高血压疾病和心血管疾病风险:孟德尔随机化研究
Lena Tschiderer1,2, Yvonne T van der Schouw2, Stephen Burgess3,4,5
1Institute of Health Economics, Medical University of Innsbruck, Innsbruck, Austria.
European heart journal
|February 2, 2024
概括
对妊娠高血压疾病 (HDPs) 的遗传倾向增加了心血管疾病 (CVD) 的风险,与高血压和早期高血压诊断有关. 这些联系表明HDP和晚年心血管疾病之间存在因果关系.
科学领域:
- 心血管科学 心血管科学
- 遗传学 是一个遗传学.
- 产科和妇科 产科和妇科
背景情况:
- 妊娠高血压疾病 (HDPs) 与怀孕后不良孕产妇心血管疾病 (CVD) 风险概况有关.
- 了解HDPs的遗传基础及其与心血管疾病的关联对于风险预测和预防至关重要.
研究的目的:
- 调查生前/生前和妊娠高血压与心血管疾病风险因素和事件之间的遗传责任之间的关联.
- 确定对HDPs的遗传倾向是否会因果影响晚年心血管疾病风险.
主要方法:
- 利用了HDPs的全基因组关联研究数据和CVD风险因素和事件的英国生物银行个人参与者数据.
- 在221,155名曾经怀孕的妇女中使用孟德尔随机化分析,在男性和无重动物中进行敏感性分析.
主要成果:
- 对HDPs的遗传责任显示心血管疾病的几率增加 (或每单位增加1.20-1.24).
- 与较高的收缩/放缩血压和较早的高血压诊断有关.
- 对男性和无重体动物的敏感性分析证实了这些发现,表明没有显著差异.
结论:
- 对HDPs的遗传责任与心血管疾病风险增加,高血压和早期高血压发作有因果关系.
- 这些发现表明,在不同人群中,HDPs与心血管风险之间存在共同的生物机制.
相关概念视频
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
01:33Hormonal Regulation
33.1K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.1K
01:27Psychoneuroimmunology: Cardiovascular Disease
31
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
31
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
448
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
448
01:11Genome-wide Association Studies-GWAS
13.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431